Cyclobenzaprine: Difference between revisions
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Toxicity== | |||
*Similar to [[Tricyclic antidepressant toxicity]], molecular structure similar and urine testing can be positive for TCAs | |||
*Can have anticholinergic toxidrome in overdose | |||
==Administration== | ==Administration== | ||
*Type: muscle relaxant | *Type: muscle relaxant | ||
| Line 8: | Line 12: | ||
*5-10mg PO 1-3 times per day | *5-10mg PO 1-3 times per day | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
* >15 y/o | |||
* 5-10 mg TID | |||
==Special Populations== | ==Special Populations== | ||
Latest revision as of 21:11, 28 October 2023
Toxicity
- Similar to Tricyclic antidepressant toxicity, molecular structure similar and urine testing can be positive for TCAs
- Can have anticholinergic toxidrome in overdose
Administration
- Type: muscle relaxant
- Dosage Forms:
- Routes of Administration: Oral
- Common Trade Names: Flexeril
Adult Dosing
- 5-10mg PO 1-3 times per day
Pediatric Dosing
- >15 y/o
- 5-10 mg TID
Special Populations
- Pregnancy Rating: B
- Lactation risk: infant risk cannot be ruled out
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult: Titrate slowly
- Pediatric:
Contraindications
- Allergy to class/drug
- MAOI use, concomitantly or within 14 days
- Heart block or other serious arrhythmias, CHF
Adverse Reactions
Serious
- Neuroleptic malignant syndrome
- Serotonin syndrome
- Stroke
- Dysrhythmias, heart block
- Bone marrow depression
- Hepatitis
Common
- Somnolence, dizziness
- Nausea, constipation
Pharmacology
- Half-life: ~18h for immediate release, 32h for extended release
- Metabolism: hepatic
- Excretion: Urine
Mechanism of Action
- Acts on CNS to reduce tonic somatic motor activity